About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: Life Sciences Tools & Services
- Exchange: NASDAQ
- Symbol: FLDM
- CUSIP: 34385P10
- Previous Close: $6.81
- 50 Day Moving Average: $6.76
- 200 Day Moving Average: $7.11
- 52-Week Range: $4.31 - $11.05
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.94
- P/E Growth: 0.38
- Market Cap: $203.47M
- Outstanding Shares: 29,150,000
- Beta: 3.17
- Net Margins: -72.75%
- Return on Equity: -72.84%
- Return on Assets: -17.99%
Companies Related to Fluidigm Corporation:
- Debt-to-Equity Ratio: 2.87%
- Current Ratio: 3.87%
- Quick Ratio: 3.13%
What is Fluidigm Corporation's stock symbol?
Fluidigm Corporation trades on the NASDAQ under the ticker symbol "FLDM."
Where is Fluidigm Corporation's stock going? Where will Fluidigm Corporation's stock price be in 2017?
4 analysts have issued twelve-month price objectives for Fluidigm Corporation's stock. Their forecasts range from $9.00 to $15.00. On average, they anticipate Fluidigm Corporation's share price to reach $12.00 in the next year.
When will Fluidigm Corporation announce their earnings?
Fluidigm Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Fluidigm Corporation stock?
Here are some recent quotes from research analysts about Fluidigm Corporation stock:
According to Zacks Investment Research, "Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company's products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California. " (2/9/2017)
Cantor Fitzgerald analysts commented, "XLRS is Progressing. A bright spot in the quarterly earnings release is the XLRS Phase I/II trial, where two patients have already been enrolled in the high dose cohort, and dose expansion data are likely in mid-2017, which is slightly ahead of prior expectations." (2/9/2017)
Who owns Fluidigm Corporation stock?
Fluidigm Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Levin Capital Strategies L.P. (19.75%), Russell Investments Group Ltd. (7.69%), State Street Corp (1.60%), Renaissance Technologies LLC (1.55%), FMR LLC (0.55%) and Intellectus Partners LLC (0.47%). Company insiders that own Fluidigm Corporation stock include Evan/ Fa Jones, Gajus Vincent Worthington, Levin Capital Strategies, LP, Mai Chan Yow, Robert C Jones, Samuel D Colella, Stephen Christopher Linthwaite, Vikram Jog and William Maxwell Smith.
Who sold Fluidigm Corporation stock? Who is selling Fluidigm Corporation stock?
Fluidigm Corporation's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and State Street Corp.
Who bought Fluidigm Corporation stock? Who is buying Fluidigm Corporation stock?
Fluidigm Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Levin Capital Strategies L.P., FMR LLC, Intellectus Partners LLC, Renaissance Technologies LLC, AQR Capital Management LLC and Metropolitan Life Insurance Co. NY. Company insiders that have bought Fluidigm Corporation stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella and Stephen Christopher Linthwaite.
How do I buy Fluidigm Corporation stock?
Shares of Fluidigm Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Fluidigm Corporation stock cost?
One share of Fluidigm Corporation stock can currently be purchased for approximately $6.98.